Zedoary and the Liver: A 2025 Human Trial and What Rodent Hepatoprotection Actually Shows

The main Curcuma zedoaria page states plainly that “the human evidence for taking zedoary rhizome for any condition is essentially absent.” Researching this page found one specific, real exception: a 2025 randomised controlled trial of zedoary for fatty liver disease — the only adequately designed human efficacy trial of the whole rhizome located anywhere in this four-page series. It deserves to be reported precisely, because the trial’s own upbeat conclusion sentence and its actual data table do not say quite the same thing, and the gap between them is the most instructive single finding in this set.

Table of Contents

  1. The Claim
  2. The 2025 NAFLD Trial, in Full
  3. Reading the Trial Honestly: Objective Versus Subjective
  4. The Classic Rodent Hepatoprotection Literature
  5. Vinegar-Processing, a Quality Marker, and a Species-Identity Wrinkle
  6. The Aristolochia Substitution Study
  7. Liver-Adjacent: Alcohol Metabolism and Drug-Metabolising Enzymes
  8. A Single Antifibrotic Cell Study
  9. Verdict and Evidence Tier
  10. What Is Not Known
  11. Practical Cautions
  12. Key Research Papers
  13. Connections

The Claim

Liver protection is not one of zedoary’s headline traditional claims in the way the digestive-bitter or blood-moving reputations are, but it appears consistently as a secondary theme across Chinese, Unani and Korean herbal medicine, usually bundled with the “breaks stasis, clears accumulation” framing already discussed on the main page. The modern research base turns out to be more substantial than that secondary billing would suggest — and it now includes a genuine, if modest and unreplicated, human trial.

The 2025 NAFLD Trial, in Full

Ashraf, Rather and Mehraj, working from a government Unani-medicine research institute in Srinagar, India, published a randomised, single-blind, active-comparator trial of Curcuma zedoaria for non-alcoholic fatty liver disease (NAFLD, now more often called MASLD) in the Arab Journal of Gastroenterology in early 2025. The design, stated precisely:

Back to Table of Contents

Reading the Trial Honestly: Objective Versus Subjective

This is where the trial has to be read carefully rather than summarised from its conclusion sentence, because the two tell different stories.

What the objective, measurable endpoints showed: no significant difference between the zedoary group and the vitamin E group. Liver span on ultrasound improved significantly in both groups with no difference between them. Fatty liver grade improved significantly in both groups, again with no significant difference between them (reported chi-squared statistic p = 0.135, comfortably above the conventional 0.05 threshold for significance). There were no changes in liver function markers or lipid parameters in either group, though the authors note zedoary produced a slight reduction in triglycerides.

What the subjective, symptom-based endpoints showed: both groups improved on most measures, but zedoary performed better than vitamin E on some of them. Anorexia resolved in 100% of the zedoary group post-treatment versus a non-significant improvement in the vitamin E group. Malaise resolved in 84% of the zedoary group versus 8% of the vitamin E group (p < 0.0001) — the single largest between-group difference in the entire trial. Dull right-upper-abdominal ache and dyspepsia improved in both groups, with zedoary showing “more favourable” or “slightly better” outcomes.

The trial’s own conclusion states that zedoary “is effective in managing NAFLD, showing better outcomes than vitamin E.” Read against the data table, that sentence is accurate only for the subjective symptom scores. On every objective, biologically verifiable measure — the actual fatty liver grade on imaging, liver span, liver enzymes, the lipid panel — zedoary performed no differently from vitamin E, and vitamin E itself has no strong established efficacy for NAFLD's underlying liver pathology either. Two comparator arms improving together on subjective malaise and appetite scores, with neither group's actual disease severity moving differently from the other, is also consistent with a general suggestion or placebo-adjacent response to any twice-daily intervention delivered inside a supportive clinical relationship — the single-blind design, with no inert placebo arm, cannot rule that out. This is not a criticism unique to zedoary; it is the ordinary limitation of a small, single-blind, active-comparator, per-protocol-only trial, and it applies exactly as much to the vitamin E arm.

What this genuinely establishes: a signal worth a properly powered, double-blind, placebo-controlled follow-up trial with intention-to-treat analysis and a longer duration — and, notably, no drug-related adverse events over 60 days at this dose, which is real and useful safety information regardless of how the efficacy question resolves. What it does not establish: that zedoary treats fatty liver disease. That claim would require the objective endpoints to move, and in this trial they did not move differently from an active comparator with no proven effect on liver histology itself.

Back to Table of Contents

The Classic Rodent Hepatoprotection Literature

Beneath the 2025 trial sits a older and more conventional preclinical literature, running back to the 1990s, using standard toxin-induced liver injury models:

Vinegar-Processing, a Quality Marker, and a Species-Identity Wrinkle

Chinese medicine vinegar-processes e zhu before using it for liver conditions specifically — already noted on the main page as a real pharmacological modification, not mere tradition. Cui and colleagues (2019) investigated this directly: comparing crude and vinegar-processed Curcuma zedoaria in cell-based oxidative liver-injury assays (hydrogen peroxide and tert-butyl hydroperoxide again), they identified epicurzerenone as a quality marker specifically associated with the vinegar-processed material’s superior hepatoprotective activity, concluding vinegar-processed zedoary is “more suitable for the treatment of oxidative liver diseases” than the crude rhizome.

This paper is also worth reading for what it says about identity, applying the marker-compound caution the main page raises about Chinese Pharmacopoeia sourcing directly to this exact citation: its own introduction describes “Curcuma zedoaria” as “dry stenophora of Curcuma phaeocaulis Val., Curcuma kwangsiensis… or Curcuma wenyujin” — the same three-species Chinese Pharmacopoeia ambiguity documented on the main Curcuma zedoaria page. A marker compound establishes potency for whatever plant material was actually tested; it says nothing about which of (at least) four possible Curcuma species produced it. Readers should treat this study, and the wider Chinese vinegar-processing literature generally, as chemistry demonstrated on Chinese-pharmacopoeia “e zhu” material of uncertain single-species origin, not necessarily on Curcuma zedoaria Roscoe specifically — the identical caution the main page already applies to the β-elemene literature.

Back to Table of Contents

The Aristolochia Substitution Study

One study in this literature runs in an unusual and genuinely favourable direction, and it deserves its own explanation. Ansari and colleagues (2021), also working within Unani medicine, investigated a specific traditional-medicine concept called abadal-i-adwiya — drug substitution, where one medicinal plant is formally recognised as standing in for another. The plant being substituted for is Aristolochia rotunda, a member of a genus responsible for one of the best-documented cases of herb-induced organ damage in the medical literature: aristolochic acid nephropathy, the kidney failure and urothelial cancer syndrome linked to Aristolochia species in several countries. The substitute proposed by Unani tradition is Curcuma zedoaria.

The study tested this directly: inducing liver injury in Wistar rats with carbon tetrachloride (CCl4), then treating separate groups with silymarin (the standard milk-thistle-derived positive control), A. rotunda extract, or C. zedoaria extract (45.73 mg/kg). Both the Aristolochia and zedoary groups showed significantly decreased bilirubin, AST and ALT compared with the untreated injury group, and microscopic examination of the liver tissue showed “significant recovery” in both treated groups. The authors’ conclusion is that zedoary may serve as a viable substitute for a plant with genuine, documented organ toxicity — a favourable finding worth stating plainly rather than folding into a generic hepatoprotection list, though the authors themselves are appropriately cautious, calling for further phytochemical and clinical corroboration before treating the substitution as settled.

Liver-Adjacent: Alcohol Metabolism and Drug-Metabolising Enzymes

Two further findings sit adjacent to hepatoprotection proper, rather than inside it, and are included because they bear directly on how zedoary interacts with the liver’s metabolic machinery rather than on liver injury itself.

Back to Table of Contents

A Single Antifibrotic Cell Study

Kim and colleagues (2005) tested a Korean preparation of Zedoariae rhizoma against cultured human hepatic myofibroblast cells — the cell type responsible for laying down the scar tissue of liver fibrosis — and found growth-inhibitory activity. This is a single in-vitro study on one specific cell process (myofibroblast proliferation) rather than a whole-liver fibrosis model, and should be weighted accordingly: a plausible early signal for an antifibrotic mechanism, not evidence that zedoary treats or prevents cirrhosis.

Verdict and Evidence Tier

Back to Table of Contents

What Is Not Known

  1. No double-blind, placebo-controlled trial of zedoary for NAFLD or any other liver condition exists — the 2025 trial is single-blind with an active, unproven comparator.
  2. No intention-to-treat analysis of the 2025 trial exists; 18 of 68 randomised patients (26%) were excluded from the per-protocol result, and what happened to them is not reported.
  3. No replication of the 2025 trial by an independent centre.
  4. No dose-finding data in humans beyond the single 500 mg twice-daily dose tested.
  5. No data on zedoary in more severe liver disease (grade 3 NAFLD, established fibrosis, cirrhosis, viral or alcohol-related hepatitis) — the trial enrolled only mild-to-moderate NAFLD.
  6. No quantification of the CYP3A4-inhibition finding at any dose a person would actually consume, so no way to predict the size of a real drug interaction.

Practical Cautions

Anyone with diagnosed fatty liver disease or any other liver condition should not read the 2025 trial as evidence that zedoary is an established treatment, and should not substitute it for standard care — weight management, addressing metabolic risk factors, and physician-directed monitoring — on the strength of a single 60-day, single-blind, 50-patient trial with a null result on every objective measure. The main Curcuma zedoaria page’s existing cautions about gallstones and biliary obstruction apply here without modification: Curcuma species stimulate bile flow, which is not a benefit where a duct is obstructed. The CYP3A4-inhibition finding above adds a specific, mechanistically grounded reason — not just a generic “herbs can interact with drugs” caution — to tell a physician about zedoary use if taking any medication metabolised by that enzyme, which includes a very large fraction of commonly prescribed drugs.

Back to Table of Contents

Key Research Papers

  1. Ashraf A, Rather SA, Mehraj M. Evaluation of Curcuma zedoaria Rosc. in the management of non-alcoholic fatty liver disease: a randomized, single blind, controlled trial. Arab Journal of Gastroenterology. 2025;26(1). The human trial discussed in full above.
  2. Matsuda H, Ninomiya K, Morikawa T, Yoshikawa M. Inhibitory effect and action mechanism of sesquiterpenes from Zedoariae Rhizoma on D-galactosamine/lipopolysaccharide-induced liver injury. Bioorganic & Medicinal Chemistry Letters. 1998;8(4). The classic mouse hepatoprotection study, ten sesquiterpenes tested.
  3. Ansari AP, Sana SH, Dar MY, Goswami P, Ahmed NZ. Validation of Unani concept of Abadal-i-Adwiya (drug substitution) by physicochemical standardization and hepatoprotective activity of Aristolochia rotunda Linn. and its substitute Curcuma Zedoaria Rosc. in albino Wistar rats. Journal of Complementary and Integrative Medicine. 2021;19(4). The Aristolochia-substitution finding.
  4. Chen K, Li G, Cui H, et al. Systems pharmacology and GC-MS metabolomics reveal the efficacy and mechanisms of zedoary oil on acute liver injury induced by oxidative stress. Phytomedicine. 2022;104. In-vitro L02 hepatocyte protection.
  5. Cui H, Zhang B, Li G, et al. Identification of a quality marker of vinegar-processed Curcuma zedoaria on oxidative liver injury. Molecules. 2019;24(11). Also the source of the species-identity caution above.
  6. Kim DI, Lee TK, Lim IS, Kim H, Lee YC, Kim CH. The inhibitory effect of a Korean herbal medicine, Zedoariae rhizoma, on growth of cultured human hepatic myofibroblast cells. Life Sciences. 2005;76(15).
  7. Ayati Z, Ramezani M, Amiri MS, et al. Ethnobotany, phytochemistry and traditional uses of Curcuma spp. and pharmacological profile of two important species (C. longa and C. zedoaria): a review. Current Pharmaceutical Design. 2019;25(8).
  8. Rodseeda C, et al. Inhibitory effects of Thai herbal extracts on the cytochrome P450 3A-mediated metabolism of gefitinib, lapatinib and sorafenib. Toxicology Reports. 2022;9. The CYP3A4 drug-interaction grounding.
  9. Kimura Y, et al. Effects of the extracts and an active compound curcumenone isolated from Curcuma zedoaria rhizomes on alcohol-induced drunkenness in mice. Fitoterapia. 2013;84.
  10. Lobo R, Prabhu KS, Shirwaikar A, Shirwaikar A. Curcuma zedoaria Rosc. (white turmeric): a review of its chemical, pharmacological and ethnomedicinal properties. Journal of Pharmacy and Pharmacology. 2009;61(1).

Connections

Back to Table of Contents